Biological E’s vaccine efficacy same as Novavax: Government panel chief

Updated on Jun 18, 2021 07:00 AM IST

Earlier this month, the Union health ministry announced that it had finalised arrangements with the Hyderabad-based vaccine manufacturer to reserve 300 million doses

On Monday, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based Covid-19 vaccine
On Monday, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based Covid-19 vaccine
By, New Delhi

Biological E’s made- in-India Covid-19 vaccine has shown very promising results in the initial trials and could have similar efficacy as that of US’ Novavax vaccine because of having a similar platform, Dr N K Arora, chief of the Centre’s Covid working group, said on Thursday.

On Monday, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based Covid-19 vaccine that Serum Institute of India is locally manufacturing as Covovax, has demonstrated 100% protection against moderate and severe disease, and an overall efficacy of 90.4%.

“Biological E’s vaccine is being developed on a similar platform and that is why we are hopeful that it will also have around 90% or above efficacy. If trials go as planned, we should have the vaccine out for use by October this year,” Arora said.

The cost of the vaccine could be as low as 250 per two doses.

“That is the estimated price that is being talked about but the final price could be different,” he said.

Earlier this month, the Union health ministry announced that it had finalised arrangements with the Hyderabad-based vaccine manufacturer to reserve 300 million doses, even though the results of the phase I/II trials are yet to be made public and phase III trial is still underway.

“These vaccine doses will be manufactured and stockpiled by M/s Biological-E from August-December 2021... ,” the ministry had said in a statement

Get Latest India Newsalong with Latest Newsand Top Headlinesfrom India and around the world.
SHARE THIS ARTICLE ON
  • ABOUT THE AUTHOR

    Rhythma Kaul works as an assistant editor at Hindustan Times. She covers health and related topics, including ministry of health and family welfare, government of India.

SHARE
Story Saved
OPEN APP
×
Saved Articles
Following
My Reads
My Offers
Sign out
New Delhi 0C
Monday, February 06, 2023
Start 15 Days Free Trial Subscribe Now
Register Free and get Exciting Deals